caprotec bioanalytics Announces Further Patent Protection Of Its CCMS Technology

02-08-2012: caprotec bioanalytics GmbH announced the issuance of patents in the US, Japan, Canada, Australia and Israel related to methods and composition of matter of its proprietary Capture Compound Mass Spectrometry (CCMS) technology.

Issued US Patent US 7,858,560 titled “Capture Compounds, Collections thereof and Methods for Analyzing the Proteome and Complex Compositions” broadly covers basic bioanalytical principles and applications of the CCMS technology. Three further US applications covering compounds and methods for applying CCMS technology to drug target elucidation and drug design are pending.  
 
Newly granted Australian Patent AU2006249219 covers capture compounds and methods for analyzing drug interactions. The newly granted Japanese Patent No JP4741458 describes the use of CCMS technology for lead optimization and risk assessment of candidate drugs to make an informed go or no-go decision to enter the clinical trial phase. Newly granted Japanese Patent JP4842914 covers methods for identifying drug targets and non-targets, and capture compounds for use in such methods.

The Canadian Patent No CA2,658,334 covers capture compounds and their use in methods for identifying, separating and analyzing drug targets. Israel Patent No. 169437 covers methods for assessing drug interactions and identifying drug target and non-target proteins by CCMS technology.

“We are pleased about this significant broadening of our patent portfolio, protecting our proprietary CCMS technology and endorsing the uniqueness of this powerful proteome analysis technology,” states Dr. Hubert Köster, Founder and Chief Executive Officer of caprotec bioanalytics GmbH.